1. Immunotherapy, an evolving approach for the management of triple negative breast cancer: Converting non-responders to responders 
Mai F. Tolba, Hany A. Omar 
Critical Reviews in Oncology / Hematology 
Volume 122, Pages (February 2018)
DOI: /j.critrevonc
Copyright © 2018 Elsevier B.V. Terms and Conditions

2. Fig. 1
Diagram depicting the implemented immunotherapeutic strategies to convert non-responders triple negative breast cancer to responders. STING, stimulator of interferon genes; TGF-β, transforming growth factor beta; PEGPH20, PEGylated recombinant hyaluronidase; HDAC, Histone deacetylases; TIM-3, T-cell immunoglobulin and mucin-domain containing-3; CTLA-4, cytotoxic T lymphocyte associated protein-4; IDO-indoleamine dehydrogenase.
Critical Reviews in Oncology / Hematology  , DOI: ( /j.critrevonc )
Copyright © 2018 Elsevier B.V. Terms and Conditions